Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

05 June 2024: Review Articles  

Advancements and Emerging Therapies in the Medical Management of Uterine Fibroids: A Comprehensive Scoping Review

Jarosław Krzyżanowski ORCID logo1ABCDEF*, Tomasz Paszkowski ORCID logo1ADE, Piotr Szkodziak ORCID logo1DE, Sławomir Woźniak ORCID logo1ADEF

DOI: 10.12659/MSM.943614

Med Sci Monit 2024; 30:e943614




ABSTRACT: Uterine fibroids, benign tumors originating from uterine smooth muscle cells, vary in prevalence depending on patient ethnicity, hormonal exposure, and genetics. Due to their high incidence, these neoplasms pose a significant burden on healthcare systems. Current treatment strategies range from routine monitoring in asymptomatic cases to surgical procedures such as myomectomy or hysterectomy in symptomatic patients, with an increasing trend toward uterus-preserving or non-surgical alternatives. This review examines the existing medical treatments for uterine fibroids and delves into the potential of emerging therapies. A scoping review of the literature was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews. Medical therapies are divided into hormonal and non-hormonal treatments; however, long-term, safe, and effective treatments in the treatment of uterine fibroids are limited. In addition to established therapies, there is an increasing number of studies investigating the effect of substances such as vitamin D or green tea extract on uterine fibroids. Some studies investigate acupuncture as a possible alternative therapy. While existing treatments offer symptomatic relief and preparation for surgery, our findings point to a significant need for further research into long-term solutions, especially owing to recent limitations in the use of ulipristal acetate due to risk of liver damage. Initial studies involving vitamin D and epigallocatechin gallate are encouraging; however, additional research is required to establish definitive therapeutic roles.

Keywords: Anti-Inflammatory Agents, Non-Steroidal, Drug Therapy, Gonadotropin-Releasing Hormone, Leiomyoma, Tranexamic Acid, Ulipristal Acetate


Leiomyomas, commonly known as uterine fibroids, are benign tumors originating from the smooth muscle tissue of the uterus. These tumors are primarily composed of an abundant extracellular matrix that contains collagen, fibronectin, and proteoglycans. Each uterine fibroid is surrounded by a pseudocapsule, comprising tightly packed collagen, smooth muscle fibers, blood vessels, and neurofibers. The prevalence of uterine fibroids increases with age, reaching a peak during the fourth and fifth decades. Factors such as ethnicity, genetic background, and hormonal exposure significantly impact their development. Given their estrogen-dependent nature, fibroids are uncommon before menarche and generally shrink following menopause. Estimating the exact prevalence of uterine fibroids is challenging. A substantial number of them are asymptomatic and go unnoticed. Research indicates that uterine fibroid prevalence ranges between 5.4% and 77% in different populations, with approximately 30% of patients experiencing symptoms. Risk factors for uterine fibroids include age, reduced parity, early onset of menstruation, obesity, diabetes, polycystic ovary syndrome, and African descent [1]. Women with uterine fibroid-related symptoms often experience a reduced quality of life, impacting their emotional, physical, and social wellbeing [2].

Treatment options for uterine fibroids vary, ranging from routine monitoring in asymptomatic cases to surgical procedures, such as myomectomy or hysterectomy, in symptomatic patients. While hysterectomy is considered the definitive treatment for uterine fibroids, there is an increasing trend toward uterus-preserving or non-surgical alternatives, particularly among women who wish to avoid surgery or retain fertility [3]. Uterine artery embolization is the most widely recognized minimally invasive procedure. Ultrasound- or magnetic resonance-guided high-intensity focused ultrasound, although still experimental, show encouraging outcomes. Medical therapies are categorized into hormonal and non-hormonal treatments [1,4]. In addition to established therapies, there is an increasing number of studies investigating the effect of substances such as vitamin D and green tea extract on uterine fibroids [5]. Treatment choices are tailored to the patient’s age, symptoms, reproductive goals, and other health conditions. Pharmacotherapy, while often suitable only for short-term use, remains a critical option for patients who are unsuitable for or opposed to invasive procedures [1]. To mitigate symptoms without resorting to hormonal or surgical interventions, some patients explore complementary and alternative medicine practices, such as physical exercise, herbal remedies, dietary changes, acupuncture, and physical therapy. However, the effectiveness of these methods is difficult to assess [6,7].

In this scoping review, we aim to address key research questions that are essential to understand current state and future directions of medical treatment for uterine fibroids: What are the current, effective treatment options available for uterine fibroids, and how do they compare in terms of efficacy and patient outcomes? What are the emerging therapies in the treatment of uterine fibroids and what is their potential in terms of efficacy and safety? Our objectives are to review and synthesize current medical treatments for uterine fibroids and to explore emerging therapies, including the investigation of new drugs and alternative medical approaches.

Material and Methods

A scoping review of the literature was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension for Scoping Reviews. The Cochrane and Pubmed databases were searched using combinations of keywords: “uterine fibroids” and “drug therapy”, “tranexamic acid”, “anti-inflammatory agents, non-steroidal”, “ulipristal acetate”, “gonadotropin-releasing hormone”, “intrauterine devices, medicated”, “danazol”, “gestrinone”, “contraceptives, oral, combined”, aromatase inhibitors”, “acupuncture”, “vitamin D”, and “epigallocatechin gallate”. English language records published between 2010 and December 2023 in peer-review journals were included, to ensure an accurate interpretation and the analysis of current, high quality research. The exclusion criteria included articles written in languages other than English, individual case reports or case series, publications not focusing on gynecological diseases, and articles lacking an abstract. The evaluation process, conducted independently by 2 reviewers, was divided into 2 phases: an initial review of titles and abstracts, followed by detailed examination of the full text papers. To confirm the final selection of evidence, any discrepancies were resolved by consensus or by a third party. Information, including study design, sample size, treatment interventions, and outcomes, was extracted from the selected articles. Information regarding the approval of drugs for use was sourced from the websites of the Center for Drug Evaluation and Research (USA) and the European Medicines Agency (EMA) [8] (Figure 1). The findings were complemented by scanning the references of relevant reviews. Due to the diverse range of study designs, methodologies, and results of the articles included in this review, a calibrated form for data charting was not used. This scoping review, while systematic and structured, did not involve a formal review protocol. The methodology was adapted iteratively in response to the literature’s evolving scope. The evidence was then synthesized, discussed within the context of the existing literature on medical treatments for uterine fibroids, and presented in tabular form (Tables 1, 2).


Hormonal Treatment Options

GNRH ANTAGONISTS: GnRH antagonists, including elagolix, relugolix, and linzagolix, cause reversible suppression of the secretion of gonadotropins and ovarian hormones. They are effective in treating moderate to severe pain associated with endometriosis and abnormal uterine bleeding caused by uterine fibroids. GnRH antagonists are well tolerated and can be cost-effective; however, further research is required to compare their efficacy with that of oral contraceptives and progestins [9]. The duration of the therapy should not exceed 2 years. The most common adverse effects of GnRH antagonists are hot flushes, headaches, and bone loss. These adverse effects can be mitigated by hormonal add-back therapy (ABT). The most common ABT regimen is 1 mg estradiol and 0.5 mg norethindrone acetate [10]. Elagolix is approved by the U.S. Food and Drug Administration (FDA) for the treatment of uterine fibroids and endometriosis [11,12]. The EMA has approved relugolix for the treatment of fibroids, while approval for treating endometriosis is ongoing [13]. Linzagolix was under regulatory review in the United States until the withdrawal of its new drug application, and was recently approved by EMA for the treatment of uterine fibroids. The available form of linzagolix does not contain ABT. The dosage of linzagolix depends on the duration of therapy and whether ABT is used. It provides a treatment option for women with uterine fibroids who do not wish or cannot take ABT [14,15].

GNRH AGONISTS: Gonadotropin-releasing hormone agonists, such as triptorelin, leuprorelin, and goserelin, bind to the GnRH receptor, inhibiting the hypothalamic-pituitary axis and inhibiting female hormone secretion. They serve as a short-term treatment option for abnormal uterine bleeding and uterine enlargement associated with uterine fibroids. These agonists reduce fibroid size and decrease abnormal bleeding. However, their effect is temporary, with fibroids often returning to their original size within 3 to 9 months after treatment. Therefore, they are best used as a preoperative treatment option or as a bridging therapy to menopause or other medical therapies. In the preoperative context, they help increase hemoglobin and hematocrit levels before surgery and reduce intraoperative blood loss [15]. A comparative study of short-term administration of relugolix and leuproline in patients preoperatively showed similar benefits (uterine volume reduction and perioperative outcomes) and adverse effects [16]. Occasionally, they are used before uterine artery embolization [17]. The adverse effects of GnRH agonists include induced hypogonadism, menopausal symptoms, altered lipid profiles, and decreased bone density. Hence, using ABT is recommended to limit these adverse effects. Treatment duration typically lasts 6 or 12 months, based on which ABT is used [15].

LEVONORGESTREL-RELEASING INTRAUTERINE DEVICE: The levonorgestrel-releasing intrauterine device (LNG-IUD) provides effective, safe, and reversible contraception. It works by inhibiting endometrial proliferation, thus reducing both the quantity and duration of menstrual bleeding and preventing endometrial hyperplasia in women receiving estrogen replacement treatment. In 2009, the FDA approved it for the treatment of heavy menstrual bleeding. As the LNG-IUD is effective for up to 5 years, it can be considered as long term treatment option for abnormal uterine bleeding. Although it does not alter fibroid size, it effectively reduces abnormal uterine bleeding associated with fibroids and can be used in symptomatic treatment. However, uterine cavity deformations due to fibroids or congenital anomalies increase the risk of IUD malposition, in some cases making this treatment unsuitable. Malposition rates are also higher in patients with a retroverted uterus and structural abnormalities, such as a septate or bicornuate uterus [15,18,19].

MEDROXYPROGESTERONE ACETATE: Depot medroxyprogesterone acetate (DMPA) is a long-acting, injectable contraceptive. Artificial progestogens inhibit follicle maturation and suppress the synthesis of ovarian estradiol. Moreover, initial studies have suggested an inverse correlation between the use of DMPA and uterine fibroids [20]. In recent article based on the 5-year cohort of the Study of Environment, Lifestyle and Fibroids, Harmon et al explored the correlation between DMPA usage and the development of uterine fibroids. Among 1610 women aged 23 to 35 years, those exposed to DMPA in the last 2 years, compared to never users, exhibited a lower growth rate of uterine fibroids and a decreased risk of fibroid development (5.2% vs 10.7%). These changes in young women can potentially delay the onset of symptoms and minimize the necessity for invasive treatment [21]. Nonetheless, further studies are needed to support these findings.


Combined oral contraceptives (COCs) are commonly used for symptomatic uterine fibroids, particularly in addressing heavy menstrual bleeding and dysmenorrhea. Although they do not reduce fibroid size, COCs significantly improve quality of life by alleviating associated symptoms and reducing blood loss in patients with heavy menstrual bleeding [15]. Some studies suggest a potential protective effect, particularly notable in the 30- to 40-year-old patient group, associated with long-term CoC use [22]. However, the use of COCs is not without its limitations. They increase the risk of venous thromboembolism and can be unsuitable for women with contraindications to estrogen use, such as a history of breast cancer, liver disease, or migraine with aura [23].

AROMATASE INHIBITORS: Aromatase inhibitors act by blocking aromatase, an enzyme essential for the production of estrogen. They are commonly used in the treatment of gynecological cancers [24] but have also been investigated as a potential treatment for uterine fibroids. Studies indicate that these inhibitors can reduce uterine fibroid size and symptoms in selected patients, although common adverse effects include hot flushes, mood swings, bone loss, and vaginal dryness [25]. In a randomized clinical trial comparing letrozole with combined therapy (letrozole and cabergoline) the size of fibroids was assessed. In both groups, reduction in uterine fibroid number and volume was observed, with no significantly important difference between the groups. Patients with combined therapy more often experienced headaches, with no significant difference in other adverse effects [25]. Notably, cases of successful use of aromatase inhibitors after hysterectomy in patients with intravenous leiomyomatosis and leiomyomatosis peritonealis disseminata have been described [26,27]. Further randomized trials are necessary for the widespread use of aromatase inhibitors in the treatment of uterine fibroids, including the use of ABT in treatment.

GESTRINONE: Gestrinone, a synthetic steroid with anti-progestin and anti-estrogenic properties, has been studied for its effects on fibroid volume and overall uterine size, although data are limited. Its usage is associated with adverse effects such as acne, seborrhea, hirsutism, hot flushes, weight gain, breast size reduction, and headaches [28,29]. In meta-analysis of de Souza Pinto et al on endometriosis treatment, gestrinone showed a favorable safety profile; however, the evidence quality was low [30]. Data on the use of gestrinone in uterine fibroids are very limited, and no randomized controlled trials were found during this review.

DANAZOL: Danazol, a synthetic androgen with weak androgenic and antigonadotrophic effects, is associated with androgenic adverse effects, such as acne, hirsutism, and weight gain. As an antigonadotrophic drug, it induces hypoestrogenic symptoms, such as hot flashes, bone loss, and vaginal dryness. While danazol appears to reduce the size of fibroids while inducing endometrial atrophy and increasing hemoglobin levels, its exact mechanism of action in uterine fibroids is not clear. There is little research on the use of danazol in the treatment of symptomatic uterine fibroids, and it is likely that GnRH agonists show a superior effect in reducing fibroid size, compared with danazol. Further research is required if danazol is to be used more widely in the treatment of uterine fibroids [19].

SELECTIVE PROGESTERONE RECEPTOR MODULATORS: Selective progesterone receptor modulators (SPRMs), such as mifepristone, ulipristal acetate, vilaprisan, and asoprisnil, act as both progesterone receptor agonists and antagonists. Through their multi-mechanism action, they can provide effective control of menstrual bleeding and significant reduction of the volume of uterine fibroids. In 2008, asoprisnil failed third phase clinical trials, and ulipristal acetate was the first SPRM available on the market. Several clinical trials, including the PEARL I and PEARL II studies, have demonstrated the effectiveness of uliprictal acetate in reducing the size of fibroids, as well as in mitigating fibroid-related symptoms, while maintaining a favorable safety profile. Unfortunately, cases of severe liver damage possibly caused by ulipristal acetate use were reported, and indications for the use of ulipristal acetate in the treatment of uterine fibroids were severely limited [31]. Currently, this treatment is an option only for perimenopausal patients who are not eligible for surgery or when the surgical treatment has failed. Patients should be advised to monitor for signs and symptoms of hepatic injury. Regular monitoring of liver function is also recommended [15,32].

SELECTIVE ESTROGEN RECEPTOR MODULATORS: Selective estrogen receptor modulators (SERMs) interact with estrogen receptors, exerting either agonist or antagonist effects, depending on the tissue type. Some studies suggested a correlation between SERM use and significant reduction in uterine fibroid volume. In an in vitro study involving human leiomyoma cells, decreased cell viability after SERM treatment was observed. However, the effect was more significant in the mifepristone and leuprolide acetate groups [33]. Despite these findings, data on SERM use in patients are limited and lack consistency. Thus, further studies are required to assess the viability of SERMs as a treatment option for uterine fibroids [34].

SELECTIVE ESTROGEN RECEPTOR DEGRADERS: Selective estrogen receptor degraders (SERDs) create a protein complex that causes the degradation of estrogen receptor protein. They have demonstrated efficacy in blocking tumor growth in breast cancer models, with fulvestrant being the first SERD approved for breast cancer treatment. While their impact on uterine fibroids remains uncertain, given the estrogen dependence of uterine fibroids, it may be beneficial to investigate the influence of SERDs on leiomyoma cells [35].

TRANEXAMIC ACID: Tranexamic acid, an antifibrinolytic drug, effectively prevents fibrin degradation. It is a non-hormonal treatment and has shown effectiveness in the treatment of menorrhagia and seems to be effective in fibroid-related abnormal uterine bleeding; however, data in this area are limited [15]. Tranexamic acid is beneficial before and during surgery. Its use during menstruation allows to reduce blood loss and increase the level of hemoglobin before the procedure. Intravenous administration of tranexamic acid immediately before or during surgery reduces perioperative blood loss, leading to a decreased risk of needing blood transfusion during or after surgery [36]. Notably, tranexamic acid does not increase the risk of venous thrombosis. Generally well-tolerated, its adverse effects are minimal, most often including gastrointestinal symptoms, such as nausea or vomiting. Other possible adverse effects include headache, back pain, and menstrual discomfort [19,37]. The role of tranexamic acid in treating fibroids requires further randomized trials. Nevertheless, its use in selected cases, especially in surgical preparation or during the perioperative period, is beneficial and is associated with reduced blood loss and lower complications risk.

NON-STEROIDAL ANTI-INFLAMMATORY DRUGS: Non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to reduce menstrual blood loss. They act by inhibiting cyclooxygenase, thus reducing the synthesis or prostaglandins in the endometrium. A 2019 Cochrane review noted limited evidence for the efficacy of NSAIDs in the treatment of abnormal uterine bleeding, with mefenamic acid being the most researched drug. While NSAIDs reduce heavy bleeding, alternatives such as danazol, LNG-IUD, and tranexamic acid may be more effective. Although NSAIDs reduce heavy menstrual bleeding, some patients can still experience menorrhagia during treatment [38]. Still, NSAIDs are a viable supplementary treatment option for profuse vaginal bleeding associated with uterine fibroids, especially in patients not accepting or not eligible for other treatments.

VITAMIN D: Vitamin D, a group of steroid compounds, plays a crucial role in cellular functions and calcium-phosphate balance. Vitamin D can be synthesized through sunlight exposure or obtained from the diet, predominantly from fatty fish, fortified foods, and supplements. Studies conducted so far have shown a reduced number of vitamin D receptors, as well as relative hypovitaminosis D, in the tissue of uterine fibroids than in normal myometrium [39–41]. Early clinical findings suggest an inverse correlation between vitamin D serum concentrations and the prevalence of uterine fibroids. In the future, vitamin D may become a component in both prevention and treatment of uterine fibroids; however, randomized trials are necessary to confirm preliminary results [5].

GREEN TEA: Epigallocatechin gallate (EGCG), the predominant catechin in green tea, is known for its antioxidant, anti-proliferative, and anti-angiogenic properties. It appears to promote apoptosis in uterine fibroid cells and decrease the levels of some proteins involved in cell-cycle progression. Several studies have analyzed the effect of EGCG on women. It seems to alleviate symptoms, increase quality of life, and, in some studies, was associated with reduction of uterine fibroid size. Further studies may pave the way for green tea EGCG-rich extracts as method of prevention and treatment of uterine fibroids [5].

CLOSTRIDIUM HISTOLYTICUM COLLAGENASE: Clostridium histolyticum collagenase (CHC) is made up of class I and class II collagenases, which possess binding capabilities with interstitial collagens. Approved by the FDA in 2010 for the treatment of Dupuytren contracture, CHC has garnered interest for its potential effect on uterine fibroids. In an ex vivo study conducted by Brunengraber et al, a decrease in uterine fibroid stiffness was noted following CHC injection [42]. Additionally, a study assessing the safety of CHC injection in women prepared for hysterectomy reported no significant adverse events, with injected fibroids demonstrating a 21% reduction in collagen density. Nevertheless, further research is needed to assess the viability of CHC as a treatment option for uterine fibroids [43].

BIODEGRADABLE THERMORESPONSIVE DRUG DELIVERY SYSTEMS: Biodegradable materials engineered for drug protection and delivery are currently under development, offering the potential for drug administration via a single injection. These drugs exert their effects locally, while the delivery system gradually degrades over a specified period of time. These advancements hold promise for women seeking to avoid more invasive procedures in the future [44].

CHINESE HERBAL PREPARATIONS: Chinese herbal preparations, particularly the Guizhi Fuling formula, have emerged as a promising treatment option of uterine fibroids. These preparations exert their effects through various mechanisms, including the modulation of hormone levels, induction of apoptosis, and inhibition of fibroid cell proliferation. A recent meta-analysis suggested the potential superiority of combined therapy involving mifepristone and Guizhi Fuling capsules, compared with mifepristone alone. However, authors emphasized the low quality of available data and underscored the need for high-quality randomized trials to prove initial findings [45].

PHYTOCHEMICALS: Plant-derived compounds, known as phytochemicals, exhibit disease-preventive characteristics and contribute to the vibrant coloration of plants. These beneficial compounds are plentiful in a variety of foods, such as fruits, vegetables, grains, legumes, nuts, and seeds. Among the diverse array of phytochemicals are flavonoids, carotenoids, and polyphenols, renowned for their capacity to modulate cellular processes including proliferation, inflammation, fibrosis, apoptosis, and angiogenesis [46]. Isoliquiritigenin, a chalcone flavonoid employed in traditional Chinese medicine, has shown promise in inhibiting estrogen-induced fibroid growth in models of uterine leiomyoma and uterine smooth muscle cells. It diminishes cell viability and proliferation, induces cell cycle arrest, and fosters apoptosis through diverse molecular pathways [47]. With further investigation, isoliquiritigenin could emerge as a novel therapeutic avenue for uterine fibroids.

CURCUMIN: Curcumin, derived from turmeric (Curcuma longa), demonstrates potential in inhibiting the proliferation of various tumor cell lines. Despite its recognized efficacy, the precise mechanism through which it operates remains unknown. Recent investigations using mice models with a human leiomyoma xenograft have unveiled curcumin’s inhibitory prowess. Notable reduction in xenograft growth alongside diminished matrix protein production was observed. Moreover, investigations conducted in vitro using Eker rat-derived uterine leiomyoma cell lines have highlighted the significant inhibitory effect of curcumin on cell proliferation [48,49]. In another rat model study, it was demonstrated that curcumin effectively mitigated oxidative stress and histological damage induced by cyclophosphamide treatment [50]. However, to firmly establish the therapeutic potential of curcumin in treating uterine fibroids, extensive research encompassing both animal and human studies is necessary to validate initial findings.

ACUPUNCTURE: Acupuncture, a longstanding practice in Chinese medicine used to prevent and treat various diseases, has yet to show definitive effects on uterine fibroids. A randomized controlled trial to determine the influence of acupuncture on symptoms related to uterine fibroids is ongoing. Further research is necessary to determine if acupuncture has the potential to become treatment option for uterine fibroids [6,7].


Inherent to the design of this scoping review are certain limitations. Primarily, our inclusion criteria, restricted to English studies, may have led to the exclusion of relevant research published in other languages. Furthermore, while not using a calibrated form for data charting is in line with the nature of a scoping review, it may have limited the uniformity in data extraction and synthesis.

While we recognize the limitations and findings of our research, there are also several potential positive implications. First, our review emphasizes the need for further research into long-term, noninvasive treatment options for uterine fibroids, especially in the context of recent restrictions on the use of drugs, such as ulipristal acetate, which was the only drug with the potential for long-term treatment that allowed for reduction in the size of fibroids. It was useful in preoperative treatment of patients with large fibroids, suspected difficult surgery, and/or anemia caused by fibroids. Unfortunately, due to cases of severe liver damage, its preoperative use is no longer allowed. Currently, ulipristal acetate is recommended only for patients in which surgery failed or who are not eligible for operative treatment [15,31,32]. The safety and efficacy of GnRH antagonists combined with ABT were investigated for up to 2 years. Additionally, investigations involved drug withdrawal after 52 weeks of combined therapy. After therapy cessation, most patients experienced heavy menstrual bleeding relapse. In these patients, symptoms were effectively alleviated by retreatment [51]. However, further research on longer treatments, involving drug-free intervals between treatments, is necessary.

Furthermore, the promising initial results from studies on vitamin D and EGCG suggest new possibilities for future investigations and therapies [5,39–41]. Several compounds identified in this review, including vitamin D, EGCG, and curcumin, show potential in uterine fibroid prevention and symptom mitigation [5,48]. With further research, they could play a role in the prevention and treatment of uterine fibroids, potentially leading to a reduction in asymptomatic and symptomatic cases. Alternative therapies, such as Chinese herbal preparations, phytochemicals, and novel drug delivery systems, show promising initial results. However, the majority of studies identified in this scoping review were conducted in an in vitro or ex vivo setting [44–50]. Randomized studies involving large cohorts of patients are necessary to assess the safety, efficacy, and clinical utility of potential new therapies.

Finally, the insights gained from this review have the potential to inform clinical practice, offering a broader perspective on available and upcoming treatments.


Currently available medical treatment options for uterine fibroids offer primarily symptomatic treatment. Pharmacological treatments help reduce the symptoms and prepare patients with anemia for surgical treatment. In selected cases, it serves as a bridge therapy until surgical treatment or menopause, when most fibroids spontaneously decrease in size and the symptoms associated with them subside. Several drugs and dietary components are being studied for their role in uterine fibroid development and treatment; however, well-planned randomized trials are necessary to draw firm conclusions. While invasive treatment remains the only definitive solution, further studies on medical treatment of uterine fibroids are needed to establish long-term therapies.


1. Szkodziak P, Pyra K, Szkodziak F, The Lublin Protocol of the uterine arteries embolization in the treatment of symptomatic uterine fibroids: J Vis Exp, 2020(163); 61530

2. Borah BJ, Nicholson WK, Bradley L, Stewart EA, The impact of uterine leiomyomas: A national survey of affected women: Am J Obstet Gynecol, 2013; 209(4); 319e1-319.e20

3. Wang Y, Zhang S, Li C, Li B, Ouyang L, Minimally invasive surgery for uterine fibroids: Ginekol Pol, 2020; 91(3); 149-57

4. Qu Y, Xiao Z, Liu L, Uterine peristalsis before and after ultrasound-guided high-intensify focused ultrasound (USgHIFU) treatment for symptomatic uterine fibroids: Med Sci Monit, 2019; 25; 2553-60

5. Krzyżanowski J, Paszkowski T, Woźniak S, The role of nutrition in pathogenesis of uterine fibroids: Nutrients, 2023; 15(23); 4984

6. Zheng MQ, Weng C, Hu W, Efficacy assessment of acupuncture in improving symptoms of uterine fibroids: A randomized controlled trial: Medicine (Baltimore), 2020; 99(18); e20016

7. Zhang Y, Peng W, Clarke J, Liu Z, Acupuncture for uterine fibroids: Cochrane Database Syst Rev, 2010(1); CD007221

8. Page MJ, McKenzie JE, Bossuyt PM, The PRISMA 2020 statement: An updated guideline for reporting systematic reviews: BMJ, 2021; 372; n71

9. Donnez J, Dolmans MM, GnRH antagonists with or without add-back therapy: A new alternative in the management of endometriosis?: Int J Mol Sci, 2021; 22(21); 11342

10. Giudice LC, As-Sanie S, Arjona Ferreira JC, Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2): Lancet, 2022; 399(10343); 2267-79 [Erratum in: Lancet. 2022;400(10353):660]

11. : Elagolix FDA approval in the treatment of pain associated with endometriosis Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210450s000lbl.pdf

12. : Elagolix FDA approval in the treatment of uterine fibroids Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213388s000lbl.pdf

13. European Medicines Agency: Relugolix authorisation Available online: https://www.ema.europa.eu/en/documents/overview/ryeqo-epar-medicine-overview_en.pdf

14. European Medicines Agency: An overview of Yselty and why it is authorised in the EU Linzagolix Available online: https://www.ema.europa.eu/en/documents/overview/yselty-epar-medicine-overview_en.pdf

15. , Management of symptomatic uterine leiomyomas: ACOG Practice Bulletin, Number 228: Obstet Gynecol, 2021; 137(6); e100-e15

16. Takeda A, Short-term administration of oral relugolix before single-port laparoscopic-assisted vaginal hysterectomy for symptomatic uterine myomas: A retrospective comparative study with leuprorelin injection: J Obstet Gynaecol Res, 2022; 48(7); 1921-29

17. Lee WJ, Kim MD, Han K, Potential benefit of GnRH-agonist treatment before uterine artery embolization for large fibroids: MRI prediction of fibroid volume reduction: Acta Radiol, 2022; 63(10); 1425-32

18. Gerkowicz SA, Fiorentino DG, Kovacs AP, Uterine structural abnormality and intrauterine device malposition: Analysis of ultrasonographic and demographic variables of 517 patients: Am J Obstet Gynecol, 2019; 220(2); 183e1-e8

19. Kashani BN, Centini G, Morelli SS, Role of medical management for uterine leiomyomas: Best Pract Res Clin Obstet Gynaecol, 2016; 34; 85-103

20. Harmon QE, Baird DD, Use of depot medroxyprogesterone acetate and prevalent leiomyoma in young African American women: Hum Reprod, 2015; 30(6); 1499-504

21. Harmon QE, Patchel SA, Zhao S, Depot medroxyprogesterone acetate use and the development and progression of uterine leiomyoma: Obstet Gynecol, 2022; 139(5); 797-807

22. Kwas K, Nowakowska A, Fornalczyk A, Impact of contraception on uterine fibroids: Medicina (Kaunas), 2021; 57(7); 717

23. Assiri GA, Bannan DF, Alshehri GH, The contraindications to combined oral contraceptives among reproductive-aged women in an obstetrics and gynaecology clinic: A single-centre cross-sectional study: Int J Environ Res Public Health, 2022; 19(3); 1567

24. , Committee Opinion No. 663: Aromatase inhibitors in gynecologic practice: Obstet Gynecol, 2016; 127(6); e170-e74

25. Sayyah-Melli M, Mobasseri M, Gharabaghi PM, Comparing the effect of aromatase inhibitor (letrozole) + cabergoline (Dostinex) and letrozole alone on uterine myoma regression,a randomized clinical trial: Eur J Obstet Gynecol Reprod Biol, 2017; 210; 257-64

26. Mizoguchi C, Matsumoto H, Nasu K, Intravenous leiomyomatosis treated with radical hysterectomy and adjuvant aromatase inhibitor therapy: J Obstet Gynaecol Res, 2016; 42(10); 1405-8

27. Ando H, Kusunoki S, Ota T, Sugimori Y, Long-term efficacy and safety of aromatase inhibitor use for leiomyomatosis peritonealis disseminata: J Obstet Gynaecol Res, 2017; 43(9); 1489-92

28. Ciebiera M, Łukaszuk K, Męczekalski B, Alternative oral agents in prophylaxis and therapy of uterine fibroids-an up-to-date review: Int J Mol Sci, 2017; 18(12); 2586

29. Zhu Y, Zhang T, Xie S, Gestrinone inhibits growth of human uterine leiomyoma may relate to activity regulation of ERα, Src and P38 MAPK: Biomed Pharmacother, 2012; 66(8); 569-77

30. de Souza Pinto LP, Ferrari G, Dos Santos IK, Evaluation of safety and effectiveness of gestrinone in the treatment of endometriosis: A systematic review and meta-analysis: Arch Gynecol Obstet, 2023; 307(1); 21-37

31. Meunier L, Meszaros M, Pageaux GP, Acute liver failure requiring transplantation caused by ulipristal acetate: Clin Res Hepatol Gastroenterol, 2020; 44(3); e45-e49

32. Ulipristal acetate restriction of use by European Medicines Agency Available online: https://www.ema.europa.eu/en/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids_en.pdf

33. Chung YJ, Chae B, Kwak SH, Comparison of the inhibitory effect of gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM), antiprogesterone on myoma cell proliferation in vitro: Int J Med Sci, 2014; 11(3); 276-81

34. Deng L, Wu T, Chen XY, Selective estrogen receptor modulators (SERMs) for uterine leiomyomas: Cochrane Database Syst Rev, 2012; 10; CD005287

35. Hernando C, Ortega-Morillo B, Tapia M, Oral selective estrogen receptor degraders (SERDs) as a novel breast cancer therapy: Present and future from a clinical perspective: Int J Mol Sci, 2021; 22(15); 7812

36. Fusca L, Perelman I, Fergusson D, The effectiveness of tranexamic acid at reducing blood loss and transfusion requirement for women undergoing myomectomy: A systematic review and meta-analysis: J Obstet Gynaecol Can, 2019; 41(8); 1185-1192e1

37. Eder S, Baker J, Gersten J, Efficacy and safety of oral tranexamic acid in women with heavy menstrual bleeding and fibroids: Womens Health (Lond), 2013; 9(4); 397-403

38. Bofill Rodriguez M, Lethaby A, Farquhar C, Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding: Cochrane Database Syst Rev, 2019; 9(9); CD000400

39. Ciavattini A, Delli Carpini G, Serri M, Hypovitaminosis D and “small burden” uterine fibroids: Opportunity for a vitamin D supplementation: Medicine (Baltimore), 2016; 95(52); e5698

40. Othman ER, Ahmed E, Sayed AA, Human uterine leiomyoma contains low levels of 1, 25 dihdroxyvitamin D3, and shows dysregulated expression of vitamin D metabolizing enzymes: Eur J Obstet Gynecol Reprod Biol, 2018; 229; 117-22

41. Markowska A, Kurzawa P, Bednarek W, Immunohistochemical expression of vitamin D receptor in uterine fibroids: Nutrients, 2022; 14(16); 3371

42. Brunengraber LN, Jayes FL, Leppert PC: Reprod Sci, 2014; 21(12); 1452-59

43. Singh B, Sims H, Trueheart I, A phase I clinical trial to assess safety and tolerability of injectable collagenase in women with symptomatic uterine fibroids: Reprod Sci, 2021; 28(9); 2699-709

44. Taylor DK, Jayes FL, House AJ, Ochieng MA, Temperature-responsive biocompatible copolymers incorporating hyperbranched polyglycerols for adjustable functionality: J Funct Biomater, 2011; 2(3); 173-94

45. Lei Y, Yang L, Yang H, The efficacy and safety of Chinese herbal medicine Guizhi Fuling capsule combined with low dose mifepristone in the treatment of uterine fibroids: A systematic review and meta-analysis of 28 randomized controlled trials: BMC Complement Med Ther, 2023; 23(1); 54

46. Islam MS, Segars JH, Castellucci M, Ciarmela P, Dietary phytochemicals for possible preventive and therapeutic option of uterine fibroids: Signaling pathways as target: Pharmacol Rep, 2017; 69(1); 57-70

47. Lin PH, Kung HL, Chen HY, Isoliquiritigenin suppresses E2-induced uterine leiomyoma growth through the modulation of cell death program and the repression of ECM accumulation: Cancers (Basel), 2019; 11(8); 1131

48. Malik M, Britten JL, DeAngelis A, Curcumin inhibits human leiomyoma xenograft tumor growth and induces dissolution of the extracellular matrix: F S Sci, 2023; 4(1); 74-89

49. Tsuiji K, Takeda T, Li B, Inhibitory effect of curcumin on uterine leiomyoma cell proliferation: Gynecol Endocrinol, 2011; 27(7); 512-17

50. Yilmaz E, Melekoglu R, Ciftci O, The therapeutic effects of curcumin and capsaicin against cyclophosphamide side effects on the uterus in rats: Acta Cir Bras, 2018; 33(6); 499-507

51. Al-Hendy A, Venturella R, Arjona Ferreira JC, LIBERTY randomized withdrawal study: Relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids: Am J Obstet Gynecol, 2023; 229(6); 662e1-e25

In Press

Clinical Research  

Trust and Support for Cancer Research Biobanks: Insights from Cancer Patients in Poland

Med Sci Monit In Press; DOI: 10.12659/MSM.944263  

Clinical Research  

Morphological and Dimensional Analysis of the Nasopalatine Canal: Insights from Cone-Beam Computed Tomograp...

Med Sci Monit In Press; DOI: 10.12659/MSM.944424  

Clinical Research  

Hemorrhagic Cysts in the Pancreas: Risk Factors, Treatment, and Outcomes – Insights from a Single-Center Study

Med Sci Monit In Press; DOI: 10.12659/MSM.941955  

Clinical Research  

Perioperative Administration of Tranexamic Acid and Low Molecular Weight Heparin for Enhanced Blood Managem...

Med Sci Monit In Press; DOI: 10.12659/MSM.944063  

Most Viewed Current Articles

14 Dec 2022 : Clinical Research   1,421,178

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990


17 Jan 2024 : Review article   1,355,487

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799


16 May 2023 : Clinical Research   690,090

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387


01 Jan 2022 : Editorial   50,113

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952


Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750